First Trust Nasdaq Pharmaceuticals ETF

Latest First Trust Nasdaq Pharmaceuticals ETF News and Updates

  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

    By Mike Benson
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///Vaccines
    Company & Industry Overviews

    Pfizer’s Vaccines: A Look at Their Market Performance

    In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.

    By Daniel Collins
  • uploads///world _
    Earnings Report

    Allergan’s Q3 2018 Earnings: Analysts’ Estimates

    Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Sage Therapeutics’ Product Portfolio Look in September?

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

    By Mike Benson
  • uploads///Chart  Valuation Comparison
    Company & Industry Overviews

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Wall Street Analysts’ Recommendations for JNJ in January 2018

    Wall Street analysts expect Johnson & Johnson to generate EPS of $2.01 on revenues of ~$19.4 billion in 1Q18 for 9.2% growth in revenues compared to 1Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer’s 4Q17 Estimates: Products with Lower Sales

    In Pfizer’s (PFE) portfolio, a few of the products reported a lower sales trend due to competition from other products in the markets.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Wall Street Recommendations for Mylan in January 2018

    As we discussed earlier in this series, Mylan (MYL) reported revenues of $2.98 billion in 3Q17, a 2.3% decline in revenues compared to $3.06 billion in 3Q16.

    By Mike Benson
  • uploads///Chart  New
    Company & Industry Overviews

    Eli Lilly’s New Products Portfolio in 3Q17

    Eli Lilly and Co.’s (LLY) product portfolio includes Basaglar, Jardiance, Cyramza, Lartruvo, Taltz, Olumiant, and Trulicity.

    By Mike Benson
  • uploads///Opsumit
    Company & Industry Overviews

    How JNJ’s Pulmonary Hypertension Portfolio Performed in 3Q17

    In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.

    By Daniel Collins
  • uploads///Chart  EPS
    Healthcare

    Bristol-Myers Squibb’s Valuations after Its 3Q17 Earnings

    Of the 22 analysts covering Bristol-Myers Squibb, nine analysts recommend a “buy,” 11 analysts recommend a “hold,” and two analysts recommend a “sell.”

    By Mike Benson
  • uploads///Chart  Orencia
    Company & Industry Overviews

    Bristol-Myers Squibb’s Immunoscience Products

    Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.

    By Mike Benson
  • uploads///Chart  NGC
    Company & Industry Overviews

    These Pfizer’s Products Are Now Losing Market Share

    Pfizer’s (PFE) Essential Health segment reported a fall in overall revenues in 2Q17, driven by the loss of exclusivity of Celebrex and Zyvox.

    By Mike Benson
  • uploads///Chart  AHR
    Company & Industry Overviews

    Behind Merck’s Animal Health Segment Performance in 2Q17

    Merck’s (MRK) Animal Health segment includes drugs and vaccines for animals and has operations spread across more than 140 countries worldwide.

    By Mike Benson
  • uploads///Biosimilars
    Company & Industry Overviews

    What to Expect from Pfizer’s Biosimilars Business

    In 2Q17, Pfizer’s Inflectra/Remsima reported revenues of ~$94 million compared to $45 million in 2Q16.

    By Daniel Collins
  • uploads///Chart  Segment
    Company & Industry Overviews

    Performance of Eli Lilly’s Business Segments in 2Q17

    The Human Pharmaceuticals segment reported revenues of ~$5.0 billion during 2Q17, representing 10.9% growth compared to its 2Q16 revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Major Developments for Johnson & Johnson in 2Q17

    Major developments All of Johnson & Johnson’s (JNJ) segments performed positively in 2Q17. In this part. we’ll look at some developments that occurred during the quarter. Pharmaceuticals On August 21, 2017, Johnson & Johnson presented new data for its COMPASS study, a phase III study evaluating Xarelto as a treatment for coronary and peripheral artery disease. […]

    By Mike Benson
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    Pfizer’s Valuation after 2Q17 Earnings

    Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Revenue Trend in 3Q16

    In 3Q16, Johnson & Johnson’s (JNJ) top line rose 4.2% to ~$17.8 billion, driven by 4.3% operational growth in revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Bristol-Myers Squibb’s 3Q16 Estimates: Oncology Segment

    Opdivo is a human PD-1 blocking antibody used in lung cancer and melanoma treatments. Opdivo is part of BMY’s alliance with Ono Pharmaceutical.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Good News: Johnson & Johnson’s 3Q16 Revenues Expected to Rise

    Analysts expect Johnson & Johnson’s (JNJ) 3Q16 revenues to rise 3.7% to $17.7 billion. The expectation comes on the back of an increase in sales of its blockbuster drugs.

    By Mike Benson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.